

## **Press Release Archives**

### **September 05, 2003**

#### **Press reports regarding M/s. Aptech Ltd.**

The press had reports that proceeds from Aptech Limited's proposed \$30 million GDR issue would be used for funding acquisitions both IT and non-IT training facilities.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

Reply is awaited from Aptech Limited.

[Top](#)

#### **Press reports regarding M/s. EIH Ltd.**

The press had reports that the Oberoi group's promoters plan to raise their stake in EIH Limited from 42.50% to around 46% by the end of the current fiscal.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

EIH Limited has vide its letter inter-alia stated, "There are no plans whatsoever of "the promoters of the Oberoi Group (raising) their stake in EIH from the existing 42.50% to 46% by the end of the current financial years". The facts are as under: 1) No questions on "raising" the promoters holding was raised at the Press Conference. 2) When Mr. P.R.S. Oberoi was questioned on a possible increase in promoter holding after completion of the Conference his reply was that the promoters had not increased their holding in the Company during the current financial year to date, and if at all the promoters increased their holding during the remaining period of the current financial year they would need to be guided by the provisions of the SEBI Takeover Code. 3) No percentages or that there would necessarily be any promoter acquisition during the current financial year were mentioned. There has thus been no revelation of information not already in the public domain."

[Top](#)

#### **Press reports regarding M/s. CIPLA Ltd.**

The press had reports that the National Pharmaceutical Pricing Authority (NPPA) has issued notices to Cipla Limited for recovery of Rs. 100 crore in arrears for overcharging drugs.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

Cipla Limited has vide its letter inter-alia stated, "In this connection, we wish to inform you as follows: In the year 2000, the National Pharmaceuticals Pricing Authority, Govt. of India had sent notices to pay an amount of Rs. 206.18 crores towards alleged overcharging in respect of four drugs. The company had filed a writ petition in the Bombay High Court and the Hon'ble Bombay High court had quashed these notices vide its judgement dated 31st August 2001. The Govt. of India filed an appeal in the Supreme Court of India and the Hon'ble Supreme Court of India vide its judgement has remanded the matter back to the Bombay High Court for fresh determination and in the meantime, the Govt. has been given liberty to collect 50% of the overcharged amount.

Today we have received notices from the National Pharmaceutical Pricing Authority, Ministry of Chemicals & Fertilizers to pay an amount of Rs. 103.09 crores, being 50%, on account of alleged overcharging in respect of four drugs for the period upto June 2000. The said amount is demanded to be paid within 4 weeks. We are examining the legal implications in respect of the same."

[Top](#)

### **Press reports regarding M/s. Ranbaxy Laboratories Ltd.**

The press had reports that the National Pharmaceutical Pricing Authority (NPPA) has issued notices to Ranbaxy Laboratories Limited for recovery of Rs. 25 crore in arrears for overcharging drugs.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

Ranbaxy Laboratories Limited has vide its letter inter-alia stated, "We wish to inform you that pursuant to an order of the Hon'ble Supreme Court of India, the National Pharmaceutical Pricing Authority (NPPA) has sent three notices to the Company, all dated September 02, 2003 requiring the Company to deposit sums aggregating to Rs. 25.4 crores within four weeks, being 50% of the amounts allegedly overcharged in respect of three products pending adjudication by the Mumbai High Court to whom, the matter has been remanded by the Hon'ble Supreme Court."

[Top](#)

### **The Exchange has successfully completed its 885th Normal Settlement**

The Exchange has successfully completed its 885th Normal Settlement (Rolling T+2 following SEBI directive) since inception i.e., Settlement Number N - 2003170 on September 5, 2003. The settlement statistics are as follows:

Particulars	Values
	N - 2003170
Total traded quantity (lakhs)	4402.94
Total traded value (Rs. In Crores)	4965.22
Total value of the settlement (Securities) (Rs. In Crores)	937.10
Total value of the settlement (Funds) (Rs. In Crores)	271.64
Shortages for the settlement	0.55%
% of Delivery ( No. of shares delivered / No. of shares traded )	22.00%

Retail Debt Market has completed its 159th settlement, details of which are as follows :

Settlement No.	Traded Value	Settlement Value	
		Securities	Funds
2003170	Rs. 1,72,150/-	Rs. 1,59,210/-	Rs. 1,48,650/-

[Top](#)